X Bioscience PCL

X Bioscience PCL exhibits a capital structure with a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.93 and negative free cash flow of -416,127,070 THB. The negative operating cash flow of -75,291,730 THB further highlights the company's cash flow challenges. Profitability metrics are severely negative, with a return on equity of -2.165 and a return on assets of -0.7697. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating loss of -429,624,690 THB and net loss of -468,974,140 THB underscore the company's financial distress. The company's revenue is concentrated in the food business, which is its primary source of income. However, the financial snapshot does not provide detailed segment or geographic breakdowns, making it difficult to assess the diversification of its revenue streams. The company's growth trajectory is negative, with a significant net loss and negative cash flows. The outlook for the current fiscal year is concerning, and there is no indication of improvement in the next fiscal year. The company's capital expenditure of -3,591,300 THB is minimal, suggesting a lack of investment in growth initiatives. Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's financial instability could lead to future dilution through equity issuance or debt restructuring. Recent events, as disclosed in the financial snapshot, indicate a deteriorating financial position with significant losses and negative cash flows. There are no recent filings or transcripts provided to offer additional context on the company's strategic direction or operational changes.